This article is more than 5 years old. Information may no longer be current.

ThromboGenics reports €6 million in revenues in first half

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ThromboGenics reported €6 million in total revenues for the first half of 2015, according to a press release.

This includes €4.25 million in Jetrea (ocriplasmin) sales in the U.S. and €1.75 million in Alcon royalties from Jetrea sales outside the U.S. compared with €5 million and €1.7 million, respectively, in the first half of 2014.

Net loss totaled €19.2 million, or €0.53 per share, compared with €23.9 million, or €0.66 per share, in the first half of the previous year.

Selling and marketing expenses totaled €10.2 million compared with €14.3 million in the first half of 2014.

“Our current cash resources of over €100 million, along with anticipated royalty income, should support the internal development of next-generation ophthalmology products in diabetic eye disease for at least the next 3 years,” Patrik De Haes, MD, CEO of ThromboGenics, said in the release. “This time frame will allow us to generate the clinical data needed to demonstrate the value of a number of our pipeline projects.”